Your session is about to expire
← Back to Search
Behavioral Intervention
PrEP Adherence Program for Women with Trauma-Related Conditions
N/A
Waitlist Available
Led By Angela Heads, PhD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Not using PrEP for HIV prevention at the time of screening
Be older than 18 years old
Must not have
Have severe cognitive impairment that would interfere with their ability to consent, understand study procedures and/or effectively participate in therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 weeks post enrollment
Awards & highlights
No Placebo-Only Group
Summary
"This trial aims to test a new program that helps women with mental health conditions to better adhere to HIV prevention medication. The program combines education, skills training, and motivation within mental health treatment sessions. The
Who is the study for?
This trial is for cisgender women receiving treatment for trauma-related mental health conditions who are at increased risk of HIV. Participants should be interested in a program to help them start and stick with PrEP, a medication that prevents HIV. Details on specific inclusion or exclusion criteria were not provided.
What is being tested?
The study tests an integrated intervention designed to encourage starting and maintaining use of PrEP within the context of mental health care for trauma. It will be compared with standard treatments to see if it's more effective, feasible, and acceptable.
What are the potential side effects?
Potential side effects were not specified but may include those commonly associated with PrEP medications such as nausea, headache, stomach pain, weight loss, and fatigue.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am not using HIV prevention medication.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have severe cognitive issues affecting my understanding or participation in therapy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 15 weeks post enrollment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 weeks post enrollment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants who uptake PrEP
Secondary study objectives
Change in PrEP Anticipated Stigma as assessed by the PrEP Anticipated Stigma Scale
Change in PrEP attitudes as assessed by PrEP Attitudes Measure
Change in PrEP knowledge as assessed by PrEP Knowledge Questionnaire
+7 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Integrated Intervention to Promote PrEP UptakeExperimental Treatment1 Intervention
Group II: Standard Treatment ConditionActive Control1 Intervention
Find a Location
Who is running the clinical trial?
The University of Texas Health Science Center, HoustonLead Sponsor
957 Previous Clinical Trials
348,062 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,595 Previous Clinical Trials
3,328,683 Total Patients Enrolled
Angela Heads, PhDPrincipal InvestigatorThe University of Texas Health Science Center, Houston
1 Previous Clinical Trials
60 Total Patients Enrolled